Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically. Specifically, disclosed is a resistance program identified by a comprehensive single-cell profiling study in melanoma patients, which was validated in two large validation cohorts. Using a large-scale in silico prediction, CDK4/6 inhibitors were identified as a class of drugs that may reverse this resistance program. These predictions were validated in melanoma cell lines, patient-derived co-culture models, and melanoma in vivo models, which show that the combination of abemaciclib and immune checkpoint blockade (ICB) overcome intrinsic drug resistance. The present invention provides for detecting an immunotherapy resistance signature and modulating the signature with CDK4/6 inhibition.

Abstract: This invention relates generally to compositions and methods for modulating complement component 3 (C3) activity or expression to treat, control or otherwise influence tumors and tissues, including cells and cell types of the tumors and tissues, and malignant, microenvironmental, or immunologic states of the tumor cells and tissues. The invention also relates to methods of diagnosing, prognosing and/or staging of tumors, tissues and cells.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a reference signal from a network entity. The UE may transmit, to the network entity, an estimation of a frequency domain imbalance between an in-phase portion of the reference signal and a quadrature-phase portion of the reference signal based on a precoding matrix associated with transmissions from the network entity and an estimation of one or more channel conditions between the UE and the network entity. The network entity may perform an imbalance compensation operation that balances the in-phase portion and the quadrature-phase portion of the transmission chain based on the estimation of the frequency domain imbalance. The UE may receive, from the network entity, a data transmission based on transmitting the indication of the estimation of the frequency domain imbalance.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive a frequency dependent residual sideband (FDRSB) indication that indicates an average FDRSB power level associated with at least one transmission antenna of a network node. The UE may receive a communication from the network node, the receiving comprising demodulating the communication based on a state of an FDRSB correction function of the UE, the state of the FDRSB correction function being based on at least one of the average FDRSB power level or an estimated total noise level. Numerous other aspects are described.

Abstract: An apparatus for wireless communication includes a memory and a processor coupled to the memory. The processor is configured to: receive one or more signals for determining frequency dependent in-phase quadrature imbalance (FDIQI) estimates; generate one or more FDIQI estimates based on the one or more signals; and transmit the one or more FDIQI estimates to a network node.

Abstract: Provided are methods and compositions for treating cancer in a subject in need thereof. One of the top gene products in glioblastoma multiforme (GBM) is KLRB1 (also known as CD161), a C-type lectin protein that binds to CLEC2D. Binding of CLEC2D to the KLRB1 receptor inhibits the cytotoxic function of NK cells as well as cytokine secretion. KLRB1 is only expressed by small subpopulations of human blood T cells, and consequently little is known about the function of this receptor in T cells. However, preliminary data demonstrate that KLRB1 expression is induced in T cells within the GBM microenvironment. In an exemplary embodiment, a method is provided comprising administering an agent capable of blocking the interaction of KLRB1 with its ligand. The agent may comprise an antibody or fragment thereof, which may bind KLRB1 or CLEC2D.

Abstract: An apparatus for wireless communication includes a memory and a processor coupled to the memory. The processor is configured to: receive one or more signals for determining frequency dependent in-phase quadrature imbalance (FDIQI) estimates; generate one or more FDIQI estimates based on the one or more signals; and transmit the one or more FDIQI estimates to a network node.

Abstract: Embodiments disclosed herein provide methods of using somatic mutations in mitochondrial genomes to retrospectively infer cell lineages in native contexts and to serve as genetic barcodes to measure clonal dynamics in complex cellular populations. Further, somatic mutations in mitochondrial DNA (mtDNA) are tracked by single cell genomic approaches for simultaneous analysis of single cell lineage and state. Applicants further show that mitochondrial mutations can be readily detected with contemporary single cell transcriptomic and epigenomic technologies to concomitantly capture gene expression profiles and chromatin accessibility, respectively.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a slot to be associated with precoder estimation, the indication of the slot including an indication of a first precoder and one or more parameters associated with the slot. The UE may receive, from the network node and during the slot, a first one or more reference signals associated with estimating a physical channel using the first precoder and a second one or more reference signals associated with estimating a second precoder using the estimated physical channel. The UE may receive, from the network node, one or more signals based on the second precoder. Numerous other aspects are described.

Abstract: The present invention relates to genomic informatics and gene-expression profiling. Gene-expression profiles provide complex molecular fingerprints regarding the relative state of a cell or tissue. Similarities in gene-expression profiles between organic states provide molecular taxonomies, classification, and diagnostics. Similarities in gene-expression profiles resulting from various external perturbations reveal functional similarities between these perturbagens, of value in pathway and mechanism-of-action elucidation. Similarities in gene-expression profiles between organic and induced states may identify clinically-effective therapies. Systems and methods herein provide for the measurement of relative gene abundances, including unbiased selection of and construction of probes and targets designed and methods for using known properties of sparsity of measurements to reach gene abundances.

Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.

Abstract: Aspects of the present disclosure also allow for a more efficient way to correct or compensate for IQ mismatch in an environment with multiple TX antennas and multiple IQ modulators. In these environments, a received signal is a beamformed signal which is a combination of all TX antennas passing through different channels and may be received in a single RX antenna. Specifically, the RX side may estimate the composite FDRSB for the TXs and signal back a composite FDRSB to allow the TX to use a single filter to compensate for the composite FDRSB. The composite FDRSB may correspond to the equivalent FDRSB received as a sum of the individual FDRSBS of each of the IQ modulators and IQ antennas at a base station.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a reference signal from a network entity. The UE may transmit, to the network entity, an estimation of a frequency domain imbalance between an in-phase portion of the reference signal and a quadrature-phase portion of the reference signal based on a precoding matrix associated with transmissions from the network entity and an estimation of one or more channel conditions between the UE and the network entity. The network entity may perform an imbalance compensation operation that balances the in-phase portion and the quadrature-phase portion of the transmission chain based on the estimation of the frequency domain imbalance. The UE may receive, from the network entity, a data transmission based on transmitting the indication of the estimation of the frequency domain imbalance.

Abstract: Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a downlink message which may include an indication of a precoder applied to one or more downlink signals. The UE may receive the one or more downlink signals using a demodulation reference signal (DMRS) and the precoder, where the one or more downlink signals may be mismatched in gain and phase. The UE may perform an iterative channel estimation procedure to estimate the downlink channel. The UE may then perform a gain and phase mismatch equalization procedure to equalize an estimated gain and phase mismatch of the one or more downlink signals based on the estimated downlink channel and the precoder. The UE may then receive one or more equalized downlink signals in accordance with the gain and phase mismatch equalization procedure.

Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.

Abstract: The subject matter disclosed herein is generally directed to modulating T cell dysfunctional and effector states by modulating glucocorticoid and IL-27 signaling. The invention further relates to modulating immune states, such as CD8 T cell immune states, in vivo, ex vivo and in vitro. The invention further relates to diagnostic and screening methods.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive, from a network node, an indication of a phase noise power level associated with the network node. The UE may receive, from the network node, a communication without applying phase noise correction associated with the communication based at least in part on the phase noise power level and one or more conditions being satisfied. Numerous other aspects are provided.

Abstract: The subject matter disclosed herein is generally directed to detecting and modulating novel gene signatures for the treatment and prognosis of cancer. The novel gene signatures predict overall survival in cancer and can be targeted therapeutically.

Abstract: The present invention generally relates to a controlled fluidic device to develop spatially complex environments to enhance the rate of evolution in cell populations. The method further provides an enhanced understanding in the emergence, for example, drug resistance during cancer chemotherapy.